Zhi Tong Cai Jing·2025-11-11 04:04Core Viewpoint - China National Pharmaceutical Group (国药控股) shares rose over 3%, reaching a new high of 20.86 HKD this year, driven by positive market sentiment and analyst recommendations [1] Group 1: Stock Performance - The stock price increased by 3.49% to 20.78 HKD, with a trading volume of 111.2 million HKD [1] - Morgan Stanley's report indicated a 70% to 80% probability of the stock price rising within the next 30 days, with a target price set at 22.5 HKD [1] Group 2: Company Performance - Two subsidiaries of China National Pharmaceutical Group reported positive third-quarter results, indicating a positive trend for the group [1] - China National Pharmaceutical Co. (国药股份) saw a year-on-year revenue and profit increase of 4% and 13%, respectively, in the third quarter [1] - China National Accord Medicines Corporation (国药一致) reported a year-on-year revenue and net profit decline of 2% and 10%, but noted that its distribution business is stabilizing and returning to growth [1] Group 3: Market Context - The pharmaceutical distributor sector is expected to remain under market scrutiny until 2025 due to weak domestic demand and ongoing technology licensing activities in China [1] - The current valuation of China National Pharmaceutical Group, based on a projected P/E ratio of 6.5 times for 2026, suggests a favorable entry point for investors [1]